Browsing by Author "Las Heras, Macarena"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    A Mouse Systems Genetics Approach Reveals Common and Uncommon Genetic Modifiers of Hepatic Lysosomal Enzyme Activities and Glycosphingolipids
    (2023) Duran, Anyelo; Priestman, David A.; Las Heras, Macarena; Rebolledo-Jaramillo, Boris; Olguin, Valeria; Calderon, Juan F.; Zanlungo, Silvana; Gutierrez, Jaime; Platt, Frances M.; Klein, Andres D.
    Identification of genetic modulators of lysosomal enzyme activities and glycosphingolipids (GSLs) may facilitate the development of therapeutics for diseases in which they participate, including Lysosomal Storage Disorders (LSDs). To this end, we used a systems genetics approach: we measured 11 hepatic lysosomal enzymes and many of their natural substrates (GSLs), followed by modifier gene mapping by GWAS and transcriptomics associations in a panel of inbred strains. Unexpectedly, most GSLs showed no association between their levels and the enzyme activity that catabolizes them. Genomic mapping identified 30 shared predicted modifier genes between the enzymes and GSLs, which are clustered in three pathways and are associated with other diseases. Surprisingly, they are regulated by ten common transcription factors, and their majority by miRNA-340p. In conclusion, we have identified novel regulators of GSL metabolism, which may serve as therapeutic targets for LSDs and may suggest the involvement of GSL metabolism in other pathologies.
  • Thumbnail Image
    Item
    Genomic Modifiers of Neurological Resilience in a Niemann-Pick C family
    (2025) Las Heras, Macarena; Szenfeld, Benjamín; Olguín, Valeria; Rubilar, Juan Carlos; Calderón, Juan Francisco; Jimenez, Yanireth; Zanlungo Matsuhiro, Silvana; Buratti, Emanuele; Dardis, Andrea; Cubillos, Francisco A.; Klein, Andrés D.
    Niemann-Pick type C (NPC) disease, caused by pathogenic variants in the NPC1 or NPC2 genes, disrupts cellular cholesterol and glycolipids trafficking. Patients exhibit a wide spectrum of visceral and neurological manifestations, suggesting a role for genomic modifiers. To uncover the genetic basis of NPC neurological resilience, we analyzed the exomes of an NPC family with diverse phenotypes, from very mild to severe neurological involvement. Linkage analysis revealed loss-of-function (LOF) variants in CCDC115, SLC4A5, DEPDC5, ETFDH, SNRNP200, and DOCK1 that co-segregated with resistance to severe neurological signs. Biomarkers of severity are lacking in NPC. Based on LOF variants in the yeast orthologs of these genes, we successfully predicted NPC-like severity in Saccharomyces cerevisiae of different genetic backgrounds. Complementary, to associate pathways with severity, we performed RNA-seq, uncovering positive correlations between mitochondrial transcripts with cellular fitness. Finally, we modeled NPC disease in yeast lacking the sodium bicarbonate cotransporter bor1, the SLC4A5 ortholog. Deletion of bor1 enhanced cellular fitness, prevented vacuolar fragmentation, reduced sterols buildup, and improved mitochondrial function. Our study revealed modifiers/biomarkers of NPC severity, and highlighted SLC4A5 as a promising therapeutic target for this devastating disease.